Search research articles
Contact Us
Filters
Showing results (201-210 of 227) with videos related to
Page
of 23
Sort By:
Bone Marrow Transplantation
|
May 10, 2023
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
Meral Beksac, Simona Iacobelli, Linda Koster, et al.
Blood Cancer Journal
|
December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Carlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Bone Marrow Transplantation
|
August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
Rémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
Leukemia & Lymphoma
|
September 3, 2010
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
Monika Engelhardt, Josefina Udi, Martina Kleber, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Vaccines
|
November 26, 2024
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma
Khalid Shoumariyeh, Benedikt Csernalabics, Elahe Salimi Alizei, et al.
Nature Cancer
|
December 21, 2022
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Andrea Keppler-Hafkemeyer, Christine Greil, Paul R Wratil, et al.
The Lancet. Oncology
|
June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
Leukemia
|
August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 227) with videos related to
Sort By:
Page
of 23
Bone Marrow Transplantation
|
May 10, 2023
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
Meral Beksac, Simona Iacobelli, Linda Koster, et al.
Blood Cancer Journal
|
December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Carlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Bone Marrow Transplantation
|
August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
Rémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
Leukemia & Lymphoma
|
September 3, 2010
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
Monika Engelhardt, Josefina Udi, Martina Kleber, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
European Journal of Haematology
|
September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Vaccines
|
November 26, 2024
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma
Khalid Shoumariyeh, Benedikt Csernalabics, Elahe Salimi Alizei, et al.
Nature Cancer
|
December 21, 2022
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Andrea Keppler-Hafkemeyer, Christine Greil, Paul R Wratil, et al.
The Lancet. Oncology
|
June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
Leukemia
|
August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Page
of 23